Discussion Currently, most drugs for the treatment of lipid-related metabolic disorders target rate-limiting enzymes involved in lipogenesis, such as FAS, which is a key enzyme in fatty acid synthesis; DGAT (acyl CoA: diacylgycerol acyltransfer- ase), which catalyzes the final step, is the ...